Phase 3 Fabry Disease Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
Fabry Disease
Amicus Therapeutics8 enrolled11 locationsNCT06904261
Recruiting
Phase 2Phase 3
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Fabry Disease
Chiesi Farmaceutici S.p.A.22 enrolled12 locationsNCT06328608
Recruiting
Phase 2Phase 3
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
Fabry Disease
Chiesi Farmaceutici S.p.A.16 enrolled10 locationsNCT05710692
Recruiting
Phase 3
Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease
Fabry Disease
ISU Abxis Co., Ltd.24 enrolled3 locationsNCT06081062